vimarsana.com

Latest Breaking News On - Indaptus therapeutic - Page 1 : vimarsana.com

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pion.

Jeffrey-meckler
Louie-toma
Jules-abraham
Twitter
Linkedin
Nasdaq
Indaptus-therapeutics-inc
Indaptus-therapeutic
Indaptus-therapeutics
Looking-statement
Private-securities-litigation-reform
Quarterly-report

Equities Analysts Offer Predictions for Indaptus Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Free Report) – Analysts at HC Wainwright increased their FY2023 earnings estimates for shares of Indaptus Therapeutics in a research report issued on Tuesday, November 7th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.90) per share for the year, up from their previous estimate of […]

Glenr-anderson
Investment-house
Northern-trust-corp
Nasdaq
Vanguard-group-inc
Indaptus-therapeutics-company-profile
Renaissance-technologies
Indaptus-therapeutics-inc
Indaptus-therapeutics
Free-report
Indaptus-therapeutic

Here's Why We're Watching Indaptus Therapeutics' (NASDAQ:INDP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although.

Indaptus-therapeutics
Indaptus-therapeutic
Free-cash-flow
Cash-reserves
Herapeutics

HC Wainwright Comments on Indaptus Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:INDP)

HC Wainwright Comments on Indaptus Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:INDP)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Glenr-anderson
Indaptus-therapeutics-inc
Investment-house
Vanguard-group-inc
Securities-exchange-commission
Renaissance-technologies
Nasdaq
Indaptus-therapeutics-company-profile
Northern-trust-corp
Indaptus-therapeutics
Free-report

Q2 2023 EPS Estimates for Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increased by Analyst

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) – Research analysts at HC Wainwright upped their Q2 2023 earnings per share (EPS) estimates for Indaptus Therapeutics in a research report issued on Monday, March 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.63) for the quarter, up […]

Indaptus-therapeutics-inc
Northern-trust-corp
Strategy-asset-managers
Renaissance-technologies
Vanguard-group-inc
Nasdaq
Indaptus-therapeutics
Get-rating
Indaptus-therapeutic
Trust-corp
Street-corp

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.